Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
A plain-language summary of the cited sources below. Informational only — not medical advice.
Aripiprazole is an antipsychotic medication that works by affecting two chemical messenger systems in the brain: dopamine and serotonin. Rather than simply blocking these messengers (as older antipsychotics do), aripiprazole acts as a partial agonist at dopamine D2 receptors and serotonin 5-HT1A receptors, and blocks serotonin 5-HT2A receptors. This means it can help stabilise activity in these pathways without shutting them down completely.
It's approved for maintenance treatment of schizophrenia in adults, and to help prevent the recurrence of manic or mixed episodes in adults with bipolar I disorder. The body breaks down aripiprazole primarily through two liver enzymes, CYP3A4 and CYP2D6, which means other medications that affect these enzymes can change how aripiprazole works in your family member's system.
Aripiprazole has a very long half-life — around 29 days for the long-acting injectable form — which means it stays in the body for an extended period after each dose. This long duration is part of why it's used for maintenance treatment, but it also means any side effects may persist for some time.
Some effects you might notice include weight gain, trouble sleeping, restlessness or a feeling of needing to move (called akathisia), or increased anxiety. Injection site pain can occur if your family member receives the medication as an injection. More serious effects that need prompt medical attention include sudden drops in blood pressure when standing up, signs of blood cell problems (unusual bruising, infections, fever), or an increased risk of falls. The medication should not be used if your family member has a known allergy to aripiprazole or any of its inactive ingredients.
Common off-label uses observed in AU practice — none of these are TGA-approved indications for this substance. If the documented purpose is one of these, the prescription falls outside the TGA-approved set and may sit inside the chemical-restraint frame depending on jurisdiction and context.
These are practitioner observations, not TGA-approved indications. A use being off-label does not by itself imply a regulated restrictive practice; review the documented purpose against the observed function in context.
Tier 4 · Observation“It has been proposed that aripiprazole's efficacy is mediated through a combination of partial agonism at dopamine D2 and serotonin 5-HT1A receptors and antagonism at serotonin 5-HT2A receptors.”
“After administration of multiple doses of Abilify Asimtufii 960 mg or 720 mg, the estimated median aripiprazole terminal elimination half-life is 29.4 days, for both strengths.”
A plain-language summary of the cited sources below. Informational only — not medical advice.
Aripiprazole is an atypical antipsychotic whose efficacy is proposed to derive from partial agonism at dopamine D2 and serotonin 5-HT1A receptors combined with antagonism at serotonin 5-HT2A receptors. It is approved by the TGA for the treatment of schizophrenia and for maintenance treatment to prevent the recurrence of manic or mixed episodes of bipolar I disorder in adults. The only contraindication is hypersensitivity to aripiprazole or its excipients.
Aripiprazole is metabolised primarily by CYP3A4 and CYP2D6 enzymes, with dehydrogenation and hydroxylation pathways dependent on both isoforms and N-dealkylation catalysed by CYP3A4. After multiple doses of the long-acting injectable formulation, the median terminal elimination half-life is approximately 29 days. Common adverse effects include weight increase, akathisia, insomnia, anxiety, and injection site pain. Serious adverse effects include orthostatic hypotension, venous thromboembolism, leukopenia, neutropenia, agranulocytosis, and falls.
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Based on in vitro studies, CYP3A4 and CYP2D6 enzymes are primarily responsible for dehydrogenation and hydroxylation of aripiprazole, and N-dealkylation is catalysed by CYP3A4.”